Compare Recursion Pharmaceuticals Inc (RXRX) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.37 (market cap $1.81B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.18. The key difference: Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| RXRX | VCIT | |
|---|---|---|
Market Cap | $1.81B | — |
Sector | Health | Fixed Income |
52-Week High | $6.79 | $84.82 |
52-Week Low | $2.84 | $81.07 |
Enterprise Value | $1.33B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
